Immunotherapies for Infectious Diseases Congress
10 – 11 December, 2018
Lyon, France
ENYO Pharma’s CSO Eric Meldrum is participating today at the I4ID Congress (Immunotherapies for Infectious Diseases Congress) in Lyon, France. I4ID Congress is dedicated to Host-Directed Therapies to fight infectious diseases. During this event, Eric will present new data from ENYO Pharma preclinical programmes to exemplify the power of ENYO Pharma’s drug discovery approach.
“The 2nd edition I4ID2018, follows the success of the first edition,
Participation in La Matinale Santé organized by Bpifrance
ENYO Pharma’s VP Corporate Development & Strategy Nicolas Guyon-Gellin is participating today in “La Matinale Santé” organized by Bpifrance in Paris, France. Bpifrance finances businesses – at every stage of their development – through loans, guarantees and equity investments, but also offers extra financial services. During this event, Nicolas will talk about Bpifrance’s financing and investments actions in the health sector and the role of the Large Venture Fund. This will be a great opportunity to discuss how Bpifrance is currently supporting ENYO Pharma to pursue its growth and development.
HBV Cure Workshop 2018
Pietro Scalfaro, Chief Medical Officer of ENYO Pharma, has participated to the 5th edition of the International HBV Cure Workshop 2018 on November 7 -8 in Toronto, Canada. The HBV Cure Workshop is a scientific platform that allows to accelerate the research in finding a cure of hepatitis B. During this event, researchers and clinical experts had the opportunity to discuss current challenges regarding the disease and to present research outcomes.
ENYO Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV
Lyon, November 06, 2018 – ENYO Pharma, a clinical stage biotech company developing innovative drug candidates, today announced completion of its phase Ib clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of its FXR agonist compound EYP001 in patients with chronic hepatitis B virus infection (CHBV). The company highlights that EYP001 was well-tolerated by patients and induced a prolonged FXR target engagement after QD dosing over 4 weeks. ENYO Pharma will now initiate two Phase II clinical trials of EYP001 in NASH and CHBV.
Poster presentation with Novadiscovery at the ICSB 2018
ENYO Pharma is pleased to collaborate with Novadiscovery which is presenting at the ISCB today a poster titled “A logical modelling approach to prepare and accelerate the design of ODE models: Application to bile acid metabolism”. The model of bile acids metabolism was developed in the context of a project for ENYO Pharma, where the aim was to model chronic hepatitis B virus and non-alcoholic steatohepatitis (NASH).
Latest Press Release 